ÖT
Therapeutic Areas
BioNTech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BNT327 | Multiple Cancer Types | Phase 2/3 |
| COVID-19 Vaccine (BNT162b2) | COVID-19 Prevention | Approved |
| Individualized mRNA Cancer Immunotherapies | Various Solid Tumors | Phase 2/3 |
| Shared Antigen mRNA Cancer Vaccines | Cancer | Phase 2 |
| Next-generation mRNA Vaccines | Infectious Diseases | Phase 1 |
| Targeted Oncology Therapies | Cancer | Phase 1/2 |